Naseem Zojwalla
Chief Tech/Sci/R&D Officer at OLEMA PHARMACEUTICALS, INC.
Net worth: 789 978 $ as of 2024-04-29
Naseem Zojwalla active positions
| Companies | Position | Start | End |
|---|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2022-01-30 | - |
| TURG POIN | Chief Tech/Sci/R&D Officer | - | - |
| PELOTON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - | - |
| Columbia University Medical Center | Corporate Officer/Principal | - | - |
Career history of Naseem Zojwalla
Training of Naseem Zojwalla
| Temple University School of Medicine | Doctorate Degree |
| Stanford University | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
- Stock Market
- Insiders
- Naseem Zojwalla
- Experience
